- Previous Close
5.66 - Open
5.59 - Bid 5.73 x --
- Ask 5.74 x --
- Day's Range
5.22 - 5.77 - 52 Week Range
5.03 - 8.87 - Volume
12,973,000 - Avg. Volume
7,387,834 - Market Cap (intraday)
2.952B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
57.30 - EPS (TTM)
0.10 - Earnings Date --
- Forward Dividend & Yield 0.10 (1.53%)
- Ex-Dividend Date Jun 18, 2024
- 1y Target Est
--
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, nourishing and soothing, tonic products, cold and cough, children's medicine, anti-fungal, gynecology, and other treatment fields. Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidate injection, loquat cough granules, strong loquat decoction, loquat cough capsules, jinwugutong capsules, coral ringworm jing, jingwu capsules, quantianma capsules, yindanxintai dropping pills, etc. The company was founded in 1990 and is based in Shanghai, China.
www.gzsq.com1,426
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 600613.SS
View MorePerformance Overview: 600613.SS
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600613.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600613.SS
View MoreValuation Measures
Market Cap
2.91B
Enterprise Value
2.28B
Trailing P/E
56.60
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.32
Price/Book (mrq)
1.28
Enterprise Value/Revenue
1.04
Enterprise Value/EBITDA
27.13
Financial Highlights
Profitability and Income Statement
Profit Margin
2.30%
Return on Assets (ttm)
2.05%
Return on Equity (ttm)
2.14%
Revenue (ttm)
2.19B
Net Income Avi to Common (ttm)
50.41M
Diluted EPS (ttm)
0.10
Balance Sheet and Cash Flow
Total Cash (mrq)
874.14M
Total Debt/Equity (mrq)
9.99%
Levered Free Cash Flow (ttm)
199.61M